MilliporeSigma
Search Within

SRP0383

Applied Filters:
Keyword:'SRP0383'
Showing 1-6 of 6 results for "SRP0383" within Papers
Jing Huang et al.
The Journal of biological chemistry, 285(13), 9636-9641 (2010-02-02)
The tumor suppressor p53 is regulated by numerous post-translational modifications. Lysine methylation has recently emerged as a key post-translational modification that alters the activity of p53. Here, we describe a novel lysine methylation site in p53 that is carried out
Bassant Orabi et al.
Heart failure reviews, 23(3), 363-376 (2018-04-24)
Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors produce some beneficial and deleterious effects in diabetic patients not mediated by their glycemic lowering effects, and there is a need for better understanding of the molecular basis of these effects.
Levi Todd et al.
The Journal of comparative neurology, 524(1), 74-89 (2015-06-09)
Retinal progenitors in the circumferential marginal zone (CMZ) and Müller glia-derived progenitors have been well described for the eyes of fish, amphibians, and birds. However, there is no information regarding a CMZ and the nature of retinal glia in species
Shinichiro Kato et al.
Cancer discovery, 10(7), 980-997 (2020-04-10)
Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/β-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a
Jun Ueda et al.
The Journal of biological chemistry, 281(29), 20120-20128 (2006-05-17)
G9a is a SET-domain mammalian histone methyltransferase responsible for mono- and dimethylation of lysine 9 in histone H3 (H3K9) at euchromatic regions. Recently we reported that G9a forms a stoichiometric heteromeric complex with another SET-domain-containing molecule, GLP/Eu-HMTase1. Although G9a and
Yukihiro Itoh et al.
Scientific reports, 9(1), 767-767 (2019-01-27)
In the context of drug design, C-H···O hydrogen bonds have received little attention so far, mostly because they are considered weak relative to other noncovalent interactions such as O-H···O hydrogen bonds, π/π interactions, and van der Waals interactions. Herein, we
Page 1 of 1
Page 1 of 1